Followers | 2431 |
Posts | 91292 |
Boards Moderated | 7 |
Alias Born | 09/12/2003 |
Monday, June 19, 2023 6:42:45 AM
One of the most appealing aspects of this company, since its inception in 2013, is its track record of avoiding reverse stock splits (r/s). Considering that this is a biotech stock operating in the early stages of development, it is common for such companies to rely on share dilution for working capital to sustain their operations. Many triple-zero stocks dilute hundreds of millions of shares on a weekly or even daily basis. However, this company has managed to maintain a relatively low outstanding share count of only 422 million over a span of ten years, which is exceptionally rare. This demonstrated restraint in share dilution speaks volumes about the company's trustworthiness and its commitment to its shareholders.
$BDPT the upcoming IPO of a new company focusing on Myopia and Presbyopia drug treatment for both humans and animals introduces a patented treatment option applicable to veterinary and human use. Pending spin-off division, named "LIVE STOCK IMPACT," will establish a prominent position in the global drug market, serving the needs of both humans and animals.
Bioadaptives launched a new Division, Livestock Impact, with its own website and marketing program
https://www.livestockimpact.com/
The Flying C Bar Ranch (FCBR) Therapy Division has entered into an exclusive distribution agreement with LiveStock Impact Division for the marketing of its equine and canine products.
https://flyingcbar.myshopify.com/
https://www.facebook.com/flyingcbarranch1/
Flying C Bar Ranch Performance Horses
World Wellness and $BDPT have entered into a non-exclusive marketing agreement for a comprehensive weight management system. This system includes the innovative Fit Your Outfit (FYO) App, which utilizes AI to scientifically measure body composition with a single photo taken from a smartphone. Users can now accurately measure their own body fat percentage at home, with results as precise as those obtained through methods used by medical professionals.
(FYO) AI innovation is covered by International US and EU granted patents. Was developed by two of the top body composition experts in the world and will be marketed globally.
https://www.pixelcando.com/home
Feb. 03, 2022 they entered into a definitive agreement with inventor Thomas J. Mohr acquired his U.S. Patent 9,783,432B, with a laboratory to develop consumer products that will be marketed by BioAdaptives and Forms Subsidiary, MORO2, Inc., to Create New Products.
(Patent # US 9,622,970 B2 ) for Eye Health due to Myopia and Presbyopia is valued at US$570,000,000 by Grant Thornton.” (Patent # us 8,114,444 B2 ) for glucose management. The patent has a valuation of US$210/m as valued by Grant Thornton Accounting Firm.
Grant Thornton Accounting Firm is ranked top 6th worldwide, rankings based on the revenue of USD 7.2 billion.
FROM THE 10-Q - 08/2022
Effective November 15, 2021, the Company entered into a marketing agreement for an FDA-cleared Class II medical device, the Lung Flute™. The Company is also exploring agreements with other medical device manufacturers; the owners of intellectual property relating to medical devices and processes; and marketing companies associated with these manufacturers and owners.
CEO Dr. Edward E. Jacobs
Patents by Inventor Edward E. Jacobs, Jr.
https://patents.justia.com/inventor/edward-e-jacobs-jr
https://podcasts.apple.com/be/podcast/natural-green-living/id1523571157?l=nl
Dr. Edward E. Jacobs, Jr., a graduate of Princeton University and Harvard Medical school, is a biotechnology consultant with over 25 years’ experience in biopharmaceutical and medical device development, as well as, 35 years of teaching and direct patient care. Dr. Jacobs has participated in drug development process from discovery through animal and human studies, including regulatory support for FDA and international regulatory affairs, strategic planning and investor relations.
Dr. Jacobs has extensive clinical operations experience, having executed more than 15 human trials in the US, Europe, Eastern Europe, and the Republic of South Africa. He has also served as a medical monitor and liaison for clinical investigators involved with international trials with responsibility for regulatory compliance.
After completing surgical training at Harvard and research positions at the National Heart, Lung and Blood Institute, Bethesda, Maryland, and at Saint Thomas’ Hospital Medical School, London, Dr. Jacobs was a member of the Harvard Medical School staff, combining teaching with clinical practice and research. He has also served on the Scientific Advisory Board of the Armenise-Harvard Foundation and the Publications Committee for the New England Journal of Medicine Scientifically, Dr. Jacobs has made original observations in the field of tissue oxygenation therapy and water modification. His current focus is on natural products for animal and human use, anti-ageing strategy, and primitive cell biology.
He is an author of more than 40 scientific publications and is the holder of four patents.
Robert Ellis brings more than forty years of business management experience to the Company. He has worked extensively in senior positions across a variety of industry disciplines, including aerospace, electronics, communications, and international marketing. Mr. Ellis has been an executive officer in private and public companies, both major entities, start-ups, and emerging entities. He has an Accounting Degree from the University of Illinois, and is a CPA.
DD part # 1
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172123754
DD part # 2
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172140082
Best share structure
Reporting Status Audited Financials
U.S. Reporting: SEC Reporting
Authorized Shares 1,250,000,000 - 05/31/2023
Outstanding Shares - 422,991,798 - 05/31/2023
Restricted 15,491,267- 05/31/2023
Unrestricted 407,500,531 - 05/31/2023
Held at DTC 404,629,298 - 05/31/2023
If you compare the notes with other stocks traded on OCT, they are very minimal. Referring to the table below, convertible notes as of March 31, 2023, and December 31, 2022, and nonconvertible notes issued in fiscal year 2023.
Recap from last week, great posts
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172158427
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172159777
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172161312
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172163784
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172158427
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172159225
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172160620
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172159641
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172159600
Recent BDPT News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 10:00:41 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/17/2024 08:10:09 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2024 08:17:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:06:28 PM
- Form 1-A - Offering Statement [Regulation A] • Edgar (US Regulatory) • 10/11/2023 07:59:24 PM
- Form 1-Z - • Edgar (US Regulatory) • 08/24/2023 06:40:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:16:40 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM